Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Active not recruiting × relatlimab × Clear all

Phase

Phase 2 9 Phase 1 3 Phase 3 1 Phase 2/3 1 Phase 1/2 1

Status

Completed 7 Terminated 2 Recruiting 1 Not yet recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Gastroesophageal Cancer 1

Interventions

pembrolizumab 71 Nivolumab 38 Cyclophosphamide 37 Carboplatin 28 Specimen Handling 22 durvalumab 21 Paclitaxel 21 Dexamethasone 21 Lenalidomide 20 venetoclax 19 Gemcitabine 19 Radiotherapy 18 Magnetic Resonance Spectroscopy 18 Rituximab 17 Doxorubicin 16 fludarabine 15 Ipilimumab 15 Bevacizumab 15 atezolizumab 14 Biopsy 14 Vincristine 13 Etoposide 12 Cisplatin 12 Azacitidine 12 olaparib 11 Pemetrexed 11 Calcium Dobesilate 11 Oxaliplatin 10 Docetaxel 10 fludarabine phosphate 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03610711 2025-12-22

REACTION

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1/2 Active not recruiting

Gastrointestinal

Gastroesophageal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡